We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

8 hedge funds and large institutions have $217K invested in Altamira Therapeutics Ltd in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,414% more capital inflows, than outflows

Capital inflows: $302K | Capital outflows: $12K

60% more funds holding

Funds holding: 5 → 8 (+3)

6.31% less ownership

Funds ownership: 6.31% → 0% (-6.3%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CYTO Hedge Fund Activity: Q3 2023 in Review

8 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q3 2023, worth a combined $217K — up 359% from $47.3K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CYTO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $294K. The largest seller was Citadel Advisors, cutting an estimated $12K.

  • 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q3 2023, up from 5 in Q2 2023.
  • Funds reported $217K of Altamira Therapeutics Ltd stock for Q3 2023, up 359% quarter-over-quarter.
  • 3 funds opened new Altamira Therapeutics Ltd positions in Q3 2023 and 0 closed out, a net change of +3 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q3 2023 was Armistice Capital, an estimated $294K added.
  • The largest Altamira Therapeutics Ltd seller in Q3 2023 was Citadel Advisors, an estimated $12K sold.

Based on aggregated 13F filings for Q3 2023.